<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evaluation and management of drug-resistant epilepsy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evaluation and management of drug-resistant epilepsy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Evaluation and management of drug-resistant epilepsy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph I Sirven, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Garcia, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients with epilepsy whose seizures do not successfully respond to antiseizure medication therapy are considered to have drug-resistant epilepsy (DRE). This condition is also referred to as intractable, medically refractory, or pharmacoresistant epilepsy. As many as 20 to 40 percent of patients with epilepsy (roughly 400,000 people living in the United States) are likely to have refractory epilepsy. The annual cost for patients with epilepsy in the United States is estimated to be approximately 12.5 billion dollars (based on a 1995 survey); DRE contributes a substantive proportion of this cost [<a href="#rid1">1,2</a>]. People with DRE have the greatest burden of epilepsy-related disabilities, further contributing to the scope of this problem.</p><p>Because of the need to individualize therapy, no rigid set of guidelines can be applied to determine medical intractability, however, population-based studies have provided information regarding the prognosis of DRE that are helpful in making treatment decisions. Resective surgical therapy for epilepsy has the potential to eliminate seizures in many patients with localization-related DRE.</p><p>This topic discusses the evaluation and approach to the management of individuals with DRE. Other issues regarding the evaluation and treatment of individuals with seizures and epilepsy are presented separately. (See  <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2219.html" rel="external">"Evaluation and management of the first seizure in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2212.html" rel="external">"Initial treatment of epilepsy in adults"</a> and  <a class="medical medical_review" href="/z/d/html/91820.html" rel="external">"Surgical treatment of epilepsy in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2229.html" rel="external">"Vagus nerve stimulation therapy for the treatment of epilepsy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>A task force of the International League Against Epilepsy (ILAE) recommended replacing the term "intractable" with "drug-resistant" epilepsy (DRE) and proposed that "drug-resistant" be defined as the failure of adequate trials of two tolerated, appropriately chosen and administered antiseizure medications (whether as monotherapy or in combination) to achieve seizure freedom [<a href="#rid3">3</a>].</p><p>Traditionally, therapeutic failure of three antiseizure medications defined intractability (drug resistance) [<a href="#rid4">4-12</a>]. With many newer antiseizure medications available since the 1990s, it might have been expected that more, rather than fewer, drug trials would be recommended before determining drug resistance. However, several prospective case series have shown that a high likelihood of medical drug resistance can be identified after two unsuccessful trials, as with each antiseizure medication failure, the likelihood of successful treatment with other drugs diminishes [<a href="#rid3">3,6-14</a>]. As an example, in one study, 1098 adolescent and adult patients with a diagnosis of epilepsy were started de novo on antiseizure medication treatment and followed up to 25 years (median of 7.5 years) [<a href="#rid13">13</a>]. With the first antiseizure medication trial, 49 percent became seizure free. A second medication trial produced remission in an additional 13 percent, while only a further 4 percent became seizure-free on a third medication regimen. In this cohort, these patterns of antiseizure medication responsiveness largely persisted over time.</p><p>Approximately one third of patients who meet this definition of DRE subsequently achieve prolonged (12 months or more) periods of seizure remission [<a href="#rid15">15-17</a>]. However, the risk of seizure relapse in these individuals remains high, greater than 70 percent in one series [<a href="#rid15">15</a>].</p><p>Frequency and severity of seizures are less commonly included in a definition of DRE [<a href="#rid5">5,18</a>]. These can vary among individuals with DRE and are important considerations when weighing treatment options. Similarly, it is important to understand the impact of seizures in the context of the individual's life, job, and other psychosocial circumstances [<a href="#rid19">19</a>]. Even infrequent seizures can have a large impact.</p><p>Less often considered, but also important, is the burden of adverse effects of antiseizure medications that a patient experiences. If seizures can be controlled only at medication doses that produce disabling side effects, it may be reasonable to consider that such a person has DRE.</p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Because of unstandardized definitions as well as misdiagnoses, the incidence and prevalence of drug-resistant epilepsy (DRE) are somewhat uncertain [<a href="#rid20">20</a>]. In a systematic review of 35 observational studies that included over 13,000 patients with epilepsy and 3900 patients with DRE, the pooled prevalence of DRE was 30 percent, and the pooled incidence proportion was 15 percent [<a href="#rid20">20</a>]. Notably, only 12 percent of the studies met the requirements of the International League Against Epilepsy (ILAE) definition of DRE. (See <a class="local">'Definition'</a> above.)</p><p>A 2021 systematic review and meta-analysis, which included 103 observational studies, found that the cumulative incidence of DRE among people with epilepsy was 15 percent in adult and mixed-age studies and 25 percent in pediatric studies [<a href="#rid21">21</a>]. The prevalence of DRE among patients with an epilepsy diagnosis in population- and community-based studies was approximately 14 percent and in clinic-based studies was approximately 36 percent. There was a high level of heterogeneity and risk of bias among the included studies.</p><p class="headingAnchor" id="H4"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>A number of prospective studies have attempted to identify factors that predict the risk of DRE. These studies have varied somewhat in their sampling (population-based versus hospital-based) and whether they included children, adults, or both [<a href="#rid6">6</a>]. No single factor has been found to be uniquely useful in making accurate predictions. A combination of two or more of these factors may help to define those who are not likely to respond to medical treatment [<a href="#rid22">22,23</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response to first antiseizure medication</strong> – The response to the first antiseizure medication trial is the most important and consistently cited predictive factor among both population-based and hospital-based studies and in both adult and pediatric populations [<a href="#rid6">6,7,13,22,24-26</a>]. While more than half of patients respond to the first antiseizure medication prescribed, less than 20 percent are likely to respond to subsequent drug trials. Antiseizure medication failure due to lack of efficacy is a stronger predictor of DRE than failure due to intolerance or side effects [<a href="#rid12">12</a>]. With each number of failed antiseizure medication trials, the risk of DRE increases [<a href="#rid12">12,25,27-29</a>]. One analysis found that a seizure occurrence since the previous clinic visit or a change in antiseizure medication regimen at the previous clinic visit were important factors predicting DRE [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Seizure frequency</strong> – A high number of seizures prior to diagnosis and treatment is another consistently identified risk factor for DRE [<a href="#rid6">6-8,12,14,22-24,30-36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epilepsy etiology and pathology</strong> – The underlying etiology and seizure classification are also important. Genetic or inherited syndromes, for both generalized and localization-related epilepsy, have a better prognosis than symptomatic/cryptogenic epilepsy in both pediatric and adult populations [<a href="#rid8">8,12,13,16,20,21,23,28,30,31,37-39</a>].</p><p></p><p class="bulletIndent1">Certain pediatric epilepsy syndromes are almost invariably drug resistant. These include early infantile developmental and epileptic encephalopathy, Lennox-Gastaut syndrome, and Rasmussen encephalitis, among others. Localization-related epilepsy underlies more than half of the cases of DRE in children [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1">Among the localization-related epilepsies, those associated with vascular lesions may be more treatment responsive than those with mesial temporal sclerosis (MTS), cortical dysgenesis, or dual pathology [<a href="#rid7">7,22,37,38,40,41</a>]. Individuals with MTS have some of the highest rates of DRE, 40 to 80 percent [<a href="#rid4">4,7,9,17,40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other demographic variables</strong> – Other findings more variably associated with the risk of DRE include a presentation with status epilepticus [<a href="#rid8">8,20,27,37</a>], a longer duration of epilepsy [<a href="#rid28">28,31</a>], a family history of epilepsy [<a href="#rid12">12,14,23,30,33</a>], a history of febrile convulsions [<a href="#rid20">20,33</a>], abnormal electroencephalography (EEG) findings [<a href="#rid8">8,12,20-22</a>], and previous recreational drug use [<a href="#rid14">14</a>]. An abnormal neurologic examination and/or developmental delay are also identified as risk factors for DRE in some studies [<a href="#rid21">21,27,30,32,37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age at presentation</strong> – Some studies, but not all, suggest that age at presentation may be a factor in the development of DRE [<a href="#rid7">7,12,20,22,23,27,36,37</a>]. Some pediatric studies have found that seizure onset in later childhood or adolescence appears to be more likely to be associated with DRE than seizures with onset between the ages of 5 and 10 years [<a href="#rid8">8,32,42</a>]. Onset in the neonatal time period has been associated with DRE in at least one series [<a href="#rid32">32</a>]. Individuals who develop epilepsy later in life (&gt;65 years) appear to be less likely to develop DRE than younger adults [<a href="#rid43">43,44</a>]. The varying risk of DRE by age group likely relates to the underlying pathogenesis of epilepsy that also varies by age.</p><p></p><p>The studies cited above have generally been performed in studies examining a patient's response to initial antiseizure medication trials. However, a smaller percentage of patients with epilepsy enter remission early in their course and develop DRE later, after a period of remission that in some cases is as long as several years [<a href="#rid10">10,43</a>]. Factors that predict a later development of DRE are not well defined. However, this phenomenon of delayed intractability is most commonly described in the setting of mesial temporal sclerosis. (See <a class="local">'Pathogenesis'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>It is uncertain why seizures are or become medically resistant in any given individual. Mechanisms may vary according to the underlying disease, type of epilepsy, and antiseizure medications used for treatment  (<a class="graphic graphic_figure graphicRef130346" href="/z/d/graphic/130346.html" rel="external">figure 1</a>) [<a href="#rid45">45,46</a>].</p><p>Medical intractability may be a feature of epilepsy at the time of presentation or may evolve over time. Prospective studies with a long duration of follow-up suggest that 70 to 80 percent of patients retain their status as intractable versus in remission [<a href="#rid5">5,10,24,30,35,39,43,47-49</a>]. This means that a minority of patients with apparent drug-resistant epilepsy (DRE) are subsequently able to achieve remission and also that some patients whose seizures are initially controlled will later relapse. In the latter group, medical control can be regained with subsequent drug trials in some patients, while in others, medical intractability persists [<a href="#rid39">39,50-52</a>]. These different clinical courses may represent different mechanisms of medical intractability or pharmacoresistance.</p><p>A delayed development of intractability is most often described with epilepsy onset in childhood, particularly with epilepsy associated with mesial temporal sclerosis (MTS) [<a href="#rid10">10,39,53,54</a>]. Accumulating evidence suggests that in some individuals, MTS is a progressive condition. Pathologic studies demonstrate an evolving process involving glial proliferation and dendritic sprouting with synaptic reorganization [<a href="#rid12">12,55</a>]. Longitudinal neuroimaging studies also support a progressive process [<a href="#rid36">36,56</a>]. Alterations in neural circuitry conceivably may lead to an epileptic network that becomes drug resistant over time [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/z/d/html/2231.html" rel="external">"Focal epilepsy: Causes and clinical features"</a>.)</p><p>Studies in animal models and patients comparing drug-resistant and drug-sensitive temporal lobe epilepsy have found that the former is associated with altered expression of multidrug transporters, altered expression of antiseizure medication targets, as well as morphologic alterations in the hippocampus [<a href="#rid29">29,58</a>].</p><p>Distinguishing which of these findings is the cause versus the effect of intractable epilepsy, and whether they have clinical relevance in humans, are the subjects of ongoing investigations. As an example, some evidence supports an association between DRE and the <em>ABCB1</em> gene, which encodes an adenosine triphosphate (ATP)-dependent transporter p-glycoprotein that pumps out xenobiotic compounds from cells; overexpression of the transporter might reduce the response to antiseizure medications. A systematic review reported that six of nine studies found a significant association of <em>ABCB1</em> polymorphisms with DRE [<a href="#rid21">21</a>]. An alternative hypothesis is that overexpression of these multidrug transporters is induced by recurrent seizures, potentially providing an impetus for early aggressive seizure treatment [<a href="#rid29">29,59</a>].</p><p>Other alterations, acquired or inherited, of antiseizure medication absorption, metabolism, receptor-binding, and blood brain barrier permeability are also potential causes of pharmacoresistance [<a href="#rid60">60,61</a>].</p><p class="headingAnchor" id="H6"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Individuals with drug-resistant epilepsy (DRE) have an increased mortality rate, estimated at 1.37 per 100 person-years [<a href="#rid26">26,62-64</a>]. The standardized mortality ratio for patients with recurrent seizures is 4.69 [<a href="#rid63">63</a>]. Provided they survive the underlying cause of their seizures, individuals who become seizure free do not appear to have increased mortality [<a href="#rid65">65</a>].</p><p>Some deaths are related to the underlying cause of epilepsy (eg, cerebral neoplasm, neurodegenerative disease); other deaths are directly seizure-related, such as those that occur in the context of status epilepticus and in seizure-related accidents. Sudden unexplained death in epilepsy patients (SUDEP) is 40 times more likely among patients who continue to have seizures than in those who are seizure free [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/z/d/html/2215.html" rel="external">"Sudden unexpected death in epilepsy"</a> and  <a class="medical medical_review" href="/z/d/html/114559.html" rel="external">"Comorbidities and complications of epilepsy in adults", section on 'Premature mortality'</a>.)</p><p>Nonfatal injuries are also common in those with DRE. These include head injury, burns, and fractures, among others; most are seizure-related [<a href="#rid66">66</a>].</p><p>DRE is also associated with disability and diminished quality of life [<a href="#rid9">9,12,67,68</a>]. Examples include poor academic achievement, unemployment, and social isolation. Most patients with DRE cannot drive. In one community-based survey of people with epilepsy, those with self-reported incomplete seizure control were more likely to express concerns about the feelings of fear, their quality of life, work, adverse effects of therapy, and the stigma associated with their condition, even when their seizures were relatively infrequent [<a href="#rid69">69</a>]. These complications of DRE result from the combined effects of recurrent seizures, antiseizure medication toxicity, comorbid depression, as well as psychosocial factors such as excessive dependency [<a href="#rid9">9,12,67</a>]. (See  <a class="medical medical_review" href="/z/d/html/114559.html" rel="external">"Comorbidities and complications of epilepsy in adults", section on 'Psychosocial issues'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>When a patient's seizures do not appear to respond to antiseizure medication therapy, the clinician should reconsider the seizure classification and the appropriateness of the antiseizure medication regimens that have been employed. Clinicians should also reconsider the diagnosis of epilepsy. Misdiagnosis is common; in one series, as many as 26 percent of individuals thought to have drug-resistant epilepsy (DRE) were incorrectly diagnosed most often as a result of incomplete history-taking and/or EEG misinterpretation [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Apparent intractability</span><span class="headingEndMark"> — </span>It is important to differentiate true versus apparent DRE. Reasons for apparent treatment failure that do not reflect drug resistance include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Misdiagnosis</strong> – An incorrect diagnosis of seizure classification can lead to an incorrect drug choice [<a href="#rid71">71</a>]. It is not uncommon for idiopathic generalized epilepsy syndromes to be unrecognized and inappropriately treated with antiseizure medications that are more appropriate to localization-related epilepsy  (<a class="graphic graphic_table graphicRef78021" href="/z/d/graphic/78021.html" rel="external">table 1</a>) [<a href="#rid4">4</a>]. In some instances, a narrow-spectrum antiseizure medication can worsen seizure frequency in individuals with generalized epilepsy. One example is when <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> is prescribed for juvenile myoclonic epilepsy [<a href="#rid70">70,72,73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inappropriate dose</strong> – Inadequate dosing or frequency of antiseizure medication dosing has led to apparent intractability [<a href="#rid70">70</a>]. By contrast, seizures can also occur with antiseizure medication toxicity. This has been described in rare cases in association with <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="10144" href="/z/d/drug information/10144.html" rel="external">tiagabine</a>, and <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonadherence</strong> – Antiseizure medication adherence is frequently imperfect. In one case series, 71 percent of patients reported at least occasional dose omissions, and 45 percent reported a seizure after a missed dose [<a href="#rid74">74</a>]. Providing a nonjudgmental setting in which to elicit this history is important. Support from family members and clinicians increases medical adherence [<a href="#rid4">4,75,76</a>]. (See  <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults", section on 'Nonadherence with antiseizure medication therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lifestyle factors</strong> – Examples of lifestyle factors that can increase seizure frequency include recreational drug or alcohol use disorder and sleep deprivation [<a href="#rid4">4,33,76</a>].</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Psychogenic nonepileptic seizures</span><span class="headingEndMark"> — </span>Psychogenic nonepileptic seizure (PNES) can mimic epileptic seizures. In contrast to epileptic seizures, PNES are not associated with physiological central nervous system dysfunction but are instead psychogenically determined. PNES typically do not respond to antiseizure medication therapy. While not without limitations, video-EEG monitoring is the gold standard test for the diagnosis of PNES.</p><p>Among patients referred to epilepsy monitoring units for apparent DRE, 25 to 40 percent are diagnosed with PNES [<a href="#rid77">77,78</a>]. The clinical features, diagnosis, and treatment of PNES are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2227.html" rel="external">"Psychogenic nonepileptic seizures: Etiology, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Other nonepileptic paroxysmal disorders</span><span class="headingEndMark"> — </span>In addition to PNES, other nonepileptic paroxysmal events, especially syncope but also certain sleep and movement disorders, can be mistaken for epilepsy  (<a class="graphic graphic_table graphicRef81289" href="/z/d/graphic/81289.html" rel="external">table 2</a>) [<a href="#rid70">70,79</a>]. (See  <a class="medical medical_review" href="/z/d/html/2230.html" rel="external">"Nonepileptic paroxysmal disorders in adolescents and adults"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>Patients with drug-resistant epilepsy (DRE) should have further testing to confirm the diagnosis of epilepsy and also to better define the epilepsy syndrome and underlying classification in order to best direct treatment  (<a class="graphic graphic_algorithm graphicRef139450" href="/z/d/graphic/139450.html" rel="external">algorithm 1</a>) [<a href="#rid19">19,80</a>]. In most cases, the evaluation of DRE will include video-EEG monitoring and magnetic resonance imaging (MRI) [<a href="#rid76">76</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Video EEG monitoring</span><span class="headingEndMark"> — </span>Inpatient video-EEG monitoring combines both a video and EEG recording of clinical events. This test is used primarily to determine whether epilepsy is the cause of recurrent seizure-like events. In some series, more than 25 percent of individuals referred for monitoring for refractory epilepsy are found to have nonepileptic events, usually psychogenic nonepileptic seizures [<a href="#rid70">70</a>]. EEG monitoring can also aid in seizure classification and is used for presurgical evaluation of epilepsy patients. (See  <a class="medical medical_review" href="/z/d/html/2235.html" rel="external">"Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Neuroimaging</span><span class="headingEndMark"> — </span>By the time a patient is considered to have DRE, an MRI study will usually have been performed. In many cases, this should be repeated, particularly if the original study was unrevealing. In some cases, follow-up MRI reveals an etiology for epilepsy (such as cerebral neoplasm, autoimmune encephalitis) that was not seen on the initial study and requires specific therapies in addition to antiseizure medications [<a href="#rid81">81</a>]. The sensitivity of MRI for an underlying cause of epilepsy (so-called lesional epilepsy) can be substantially improved by using an epilepsy protocol; these are not routinely used outside of subspecialty epilepsy centers. (See  <a class="medical medical_review" href="/z/d/html/2228.html" rel="external">"Neuroimaging in the evaluation of seizures and epilepsy", section on 'Sensitivity'</a>.)</p><p>Not all MRI findings are relevant; isolated findings of diffuse atrophy, punctate foci of T2 signal abnormalities in the white matter, and other nonspecific findings are not known to be epileptogenic. MRI findings should be correlated with the patient's seizure semiology and EEG findings; some potentially epileptogenic lesions may be incidental.</p><p>In the absence of a causative lesion on MRI, an epileptogenic focus can sometimes be defined in patients with localization-related epilepsy using advanced neuroimaging techniques including positron emission tomography (PET), single photon emission computed tomography (SPECT), and magnetic source imaging (MSI). The choice of study often depends upon the availability and expertise at a particular center. The use of these tests is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2228.html" rel="external">"Neuroimaging in the evaluation of seizures and epilepsy"</a> and  <a class="medical medical_review" href="/z/d/html/91820.html" rel="external">"Surgical treatment of epilepsy in adults"</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Seizure diaries</span><span class="headingEndMark"> — </span>In some patients, it may be helpful to have them carefully record seizures, along with other relevant information, including dietary changes, timing of medication intake of both antiseizure medications and other drugs, amount and quality of sleep, and menstrual cycle changes. This may serve to improve compliance and may also help in identifying precipitants, such as hormonal changes associated with the menstrual cycle. (See  <a class="medical medical_review" href="/z/d/html/2212.html" rel="external">"Initial treatment of epilepsy in adults"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">TREATMENT OPTIONS</span><span class="headingEndMark"> — </span>Resective epilepsy surgery is the treatment of choice for medically resistant lesional partial epilepsy as this has the most likely chance of producing remission [<a href="#rid82">82</a>].</p><p>Further antiseizure medication trials, vagus nerve stimulation, deep brain stimulation, responsive cortical stimulation, and the ketogenic diet can reduce seizure frequency and improve quality of life but are more likely to be palliative, rather than curative, treatment options [<a href="#rid19">19,83</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Antiseizure medications</span><span class="headingEndMark"> — </span>Further trials of antiseizure medications in mono- or polytherapy can be of benefit in individuals with epilepsy, especially if one suspects that prior trials of antiseizure medications did not work because of adverse effects or nonadherence. It is important to review past treatment trials with the patient to assess whether the dose or frequency of dosing was adequate. The appropriateness of past antiseizure medication trials to the individual's seizure-type  (<a class="graphic graphic_table graphicRef78021" href="/z/d/graphic/78021.html" rel="external">table 1</a>) should also be specifically evaluated, as should compliance and any potential barriers to compliance. (See  <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults", section on 'Antiseizure medication therapy'</a>.)</p><p>Sequential drug trials have a small likelihood of inducing remission in patients who have already failed two or more antiseizure medication regimens. This approach can produce remission rates estimated at 4 to 6 percent per year, or a cumulative rate of 14 to 20 percent [<a href="#rid16">16,27,28,31,37,38,50</a>]. Among those who do not become seizure-free, a substantial reduction in seizure frequency is possible; in different series, 21 to 70 percent of patients achieve a 50 percent or greater reduction in seizure frequency [<a href="#rid28">28,31,37,84</a>]. Reduction in seizure severity may also improve patients' quality of life [<a href="#rid85">85</a>]. However, studies with long-term follow-up find that the benefit of successive drug trials is not sustained in one-fourth or more [<a href="#rid50">50,51,84</a>].</p><p>Choosing an antiseizure medication with a different mechanism of action than one not previously efficacious may maximize the benefit from subsequent drug trials  (<a class="graphic graphic_table graphicRef71274" href="/z/d/graphic/71274.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef60182" href="/z/d/graphic/60182.html" rel="external">table 4</a>). Some suggest that drug combinations employing antiseizure medications with different mechanisms of action may also be fruitful, although neither of these approaches has been systematically evaluated. An analysis of 70 randomized controlled trials of antiseizure medications administered as add-on therapy in patients with refractory partial epilepsy found that differences in efficacy were of too small a magnitude to allow conclusions about which antiseizure medication is more effective in this setting [<a href="#rid86">86</a>]. The approach to successive drug trials is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults", section on 'Subsequent drug trials'</a>.)</p><p>Enrollment in clinical drug trials for investigational antiseizure medications is a treatment option for patients who do not wish to proceed with current therapy, are not surgical candidates, or whose preference is to continue with medical management. Epilepsy centers and other neurologic centers often have several active ongoing research protocols.</p><p class="headingAnchor" id="H17"><span class="h2">Epilepsy surgery</span><span class="headingEndMark"> — </span>Epilepsy surgery should be considered in appropriate patients with drug-resistant epilepsy (DRE) when seizures are sufficiently frequent or severe as to significantly increase the mortality risk or disrupt the patient's quality of life. These considerations are necessarily individualized, but in general include those seizures that impair consciousness, cause injury, and occur sufficiently frequently as to be disabling [<a href="#rid87">87,88</a>]. There are no contraindications to epilepsy surgery. Thus, all patients with drug-resistant epilepsy should be assessed as to whether they are a surgical candidate as early as the failure of the first antiseizure medication. (See  <a class="medical medical_review" href="/z/d/html/91820.html" rel="external">"Surgical treatment of epilepsy in adults", section on 'Surgical evaluation'</a>.)</p><p>Early referral for epilepsy surgery is supported by 2022 expert consensus recommendations from the International League Against Epilepsy (ILAE) [<a href="#rid89">89</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Referral for a surgical evaluation should be offered to every patient with DRE up to 70 years of age as soon as drug resistance is ascertained, regardless of epilepsy duration, sex, socioeconomic status, seizure type, epilepsy type (including epileptic encephalopathies), localization, and comorbidities, including severe psychiatric comorbidity like psychogenic nonepileptic seizures (PNES) or substance abuse, if patients are cooperative with management.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgical referral should be considered for older patients with DRE who have no surgical contraindication and for adults and children who are seizure-free on one or two antiseizure medications but have a brain lesion in noneloquent cortex.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgical referral should not be offered to patients with active substance abuse who are noncooperative with management.</p><p></p><p>Resective epilepsy surgery has the best-established efficacy for individuals with lesional temporal lobe epilepsy [<a href="#rid90">90</a>]. Patients with concordant abnormalities in one temporal lobe on MRI and EEG have a rate of seizure remission as high as 90 percent [<a href="#rid91">91,92</a>]. Patients with nonlesional temporal lobe epilepsy also have a high remission rate with surgical therapy. The efficacy is highest in patients in whom EEG and another imaging modality (eg, single photon emission computed tomography [SPECT], positron emission tomography [PET], or magnetic source imaging [MSI]) reveal a consistent location of the epileptic focus.</p><p>Neocortical focal epilepsy also responds to resective surgery. As with mesial temporal lobe epilepsy, rates of seizure remission are highest in patients who have MRI lesions that are concordant with the anatomic focus of seizure activity on EEG. However, localization using SPECT, PET, and/or MSI, can also define a seizure focus that when surgically removed leads to seizure remission rates that exceed 50 percent. If noninvasive evaluations (inclusive of EEG, MRI, magnetoencephalography [MEG], and PET scans) are discordant in regard to location of a seizure generator, invasive monitoring with intracranial electrodes is often performed to determine whether a patient is a candidate for surgical resection. Invasive monitoring is useful to localize the epileptogenic focus, to assess whether cortical tissue can be resected, and to establish cortical targets for neuromodulation [<a href="#rid93">93</a>]. Stereo-EEG electrodes are increasingly used for intracranial monitoring to determine if a patient is a candidate for surgery [<a href="#rid94">94</a>].</p><p>Other surgical treatments (lobar and multi-lobar resections, hemispherectomy, corpus callosotomy, multiple subpial transections) are sometimes employed for palliative treatment in children and sometimes adults with catastrophic epilepsy syndromes.</p><p>Epilepsy surgery appears to be underutilized in patients with uncontrolled epilepsy [<a href="#rid90">90,95,96</a>]. Epilepsy surgery is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/91820.html" rel="external">"Surgical treatment of epilepsy in adults"</a> and  <a class="medical medical_review" href="/z/d/html/101361.html" rel="external">"Seizures and epilepsy in children: Refractory seizures", section on 'Epilepsy surgery'</a>.)</p><p class="headingAnchor" id="H480281665"><span class="h2">Neurostimulation</span><span class="headingEndMark"> — </span>Neurostimulation techniques should be considered for patients with drug-resistant epilepsy who are not considered candidates for focal resective epilepsy surgery [<a href="#rid97">97,98</a>]. Factors that may preclude epilepsy surgery include bilateral or multifocal areas of seizure onset, generalized seizure onset, eloquent cortex as the site of seizure onset, or significant medical comorbidities.</p><p class="headingAnchor" id="H18"><span class="h3">Vagus nerve stimulation</span><span class="headingEndMark"> — </span>Vagus nerve stimulation (VNS) is approved for adjunctive (to antiseizure medications) treatment of drug-resistant focal seizures in adults and children over 12 years of age. Approximately 30 to 40 percent of patients achieve a greater than 50 percent reduction in seizure frequency, a benefit that is sustained over time [<a href="#rid98">98-102</a>]. In a 2022 systematic review and meta-analysis of five observational studies for VNS with a mean follow-up of 1.3 years, the pooled mean decrease in seizure frequency was 34.7 percent (95% CI -5.1 to 74.5 percent) [<a href="#rid103">103</a>]. Serious adverse events are rare.</p><p>VNS is a valid treatment option for patients with well-documented DRE, who are either opposed to intracranial surgery, or who are not candidates for intracranial surgery, or whose seizures were not substantially improved by prior intracranial epilepsy surgery [<a href="#rid104">104-106</a>]. Resective surgery for appropriate candidates is preferred over VNS because of the substantially greater potential for complete seizure remission.</p><p>VNS is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2229.html" rel="external">"Vagus nerve stimulation therapy for the treatment of epilepsy"</a>.)</p><p class="headingAnchor" id="H13422344"><span class="h3">Responsive cortical stimulation</span><span class="headingEndMark"> — </span>Responsive cortical stimulation is a valid treatment option for patients with refractory focal epilepsy and a well delineated seizure focus. Although resective surgery is still preferred in such patients because it offers a substantially greater potential for complete seizure remission, cortical stimulation may be useful when resective surgery is not possible, such as an epilepsy focus in an area of eloquent cortex or individuals with multiple seizure foci. Patients with more than one seizure focus or epilepsy originating from eloquent cortex may be particularly good candidates for this device.</p><p>Responsive cortical stimulation devices employ a closed-loop cortical stimulation unit coupled to a seizure-detection system [<a href="#rid107">107-110</a>]. Open-label studies have found that this treatment may be associated with a substantial reduction in seizure number, intensity, and duration in patients with focal-onset seizures [<a href="#rid103">103</a>].</p><p>In a controlled clinical trial, 191 adults with medically intractable focal epilepsy were randomly assigned to sham or active stimulation in response to seizure detection [<a href="#rid111">111,112</a>]. After 12 weeks of therapy, the reduction in seizure frequency was greater in the active compared with the sham treatment arm (37.9 versus 17.3 percent), but the proportion of patients achieving ≥50 percent reduction in seizure frequency was similar (29 versus 27 percent; OR 1.1, 95% CI 0.6-2.1). Both active and sham treatments were associated with modest improvements in quality of life; neither mood nor cognition was negatively impacted. Electrode implantation was associated with intracranial hemorrhage in nine patients (5 percent), rated as serious in seven but without permanent neurologic sequelae. Based on these results, the US Food and Drug Administration approved the device in 2013 for use in patients with DRE.</p><p>Similar to VNS, responsive cortical stimulation appears to have sustained, or even improving, antiseizure effects over time [<a href="#rid98">98,112,113</a>]. In addition, there is indirect evidence that responsive cortical stimulation may reduce the risk of sudden unexpected death in epilepsy (SUDEP) among patients with treatment-resistant epilepsy [<a href="#rid114">114</a>].</p><p>Several small controlled trials, as well as other open label studies, have found that stimulation of the hippocampus appears to reduce seizure frequency in patients with mesial temporal lobe epilepsy [<a href="#rid115">115-118</a>], but more data are needed to establish safety and efficacy of this method [<a href="#rid119">119</a>].</p><p>A novel type of cortical stimulation is currently being evaluated by using chronic subthreshold stimulation. Early results have been promising [<a href="#rid120">120-122</a>]. A larger trial is underway.</p><p class="headingAnchor" id="H4094799885"><span class="h3">Deep brain stimulation</span><span class="headingEndMark"> — </span>Subcortical deep brain stimulation paradigms have targeted the anterior and centromedian thalamic nuclei, the subthalamic nucleus, the caudate, hippocampus, and the cerebellum [<a href="#rid123">123</a>]. Short-term open-label and small sham-controlled studies have found that stimulation in these sites reduces seizure frequency by 50 percent or more in some patients [<a href="#rid103">103,123-127</a>], although not by statistically or clinically significant amounts with short-term follow up [<a href="#rid125">125</a>].</p><p>In a randomized clinical trial of deep brain stimulation in the anterior nucleus of the thalamus (SANTE trial) in 110 patients with DRE, stimulation therapy was associated with a 29 percent reduction in seizure frequency compared with sham stimulation at three months; 54 percent of patients had a seizure reduction of at least 50 percent by two years in the unblinded phase [<a href="#rid128">128</a>]. Complex partial and "most severe" seizures were most significantly reduced by stimulation. Participants in the stimulated group were more likely to report depression (15 versus 2 percent) and memory problems (13 versus 2 percent) as adverse effects. There were five asymptomatic hemorrhages (5 percent) and 14 implant site infections (13 percent).</p><p>In a long-term follow-up study of the same trial, the responder rate was 68 percent at five years in 59 continuing patients with complete seizure diary information [<a href="#rid129">129</a>]. Measures of seizure severity and quality of life also improved over time. There were no unanticipated adverse events with extended follow up, and rates of depression, suicidality, and SUDEP were comparable to expected rates in the general refractory epilepsy population [<a href="#rid129">129,130</a>].</p><p class="headingAnchor" id="H200063487"><span class="h3">Other stimulation approaches</span><span class="headingEndMark"> — </span>Other therapeutic devices under investigation for refractory epilepsy include [<a href="#rid131">131</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transcranial magnetic stimulation</strong> – Low frequency transcranial magnetic stimulation also reduces cortical excitability [<a href="#rid132">132,133</a>]. Uncontrolled trials and case reports have suggested that this may reduce seizure frequency [<a href="#rid134">134,135</a>]. However, small controlled trials have had mixed results [<a href="#rid136">136-139</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trigeminal nerve stimulation</strong> – Low frequency (120 Hz) trigeminal nerve stimulation applied externally may reduce seizures in patients with drug resistant focal onset epilepsy [<a href="#rid140">140,141</a>]. This approach was investigated in a randomized, double-blind trial in 50 patients with two or more partial onset seizures per month [<a href="#rid140">140</a>]. Over an 18-week treatment period, external trigeminal nerve stimulation was associated with a greater response rate (&gt;50 percent decrease in seizure frequency) compared with active control stimulation (30 versus 21 percent). External trigeminal nerve stimulation was also associated with improvements in mood as measured by the Beck depression inventory. The device has been approved for use in the European Union and is still being investigated in the United States.</p><p></p><p class="headingAnchor" id="H20"><span class="h2">Ketogenic diet</span><span class="headingEndMark"> — </span>Ketogenic dietary therapy (high-fat, low carbohydrate) is an effective treatment for all patients with epilepsy, regardless of age or seizure type. A greater than 50 percent seizure reduction occurs in 38 to 60 percent of patients. The ketogenic diet is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/14438.html" rel="external">"Ketogenic dietary therapies for the treatment of epilepsy"</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Catamenial seizures</span><span class="headingEndMark"> — </span>Women with catamenial epilepsy may benefit from specific interventions to lower seizure frequency. (See  <a class="medical medical_review" href="/z/d/html/2212.html" rel="external">"Initial treatment of epilepsy in adults", section on 'Catamenial epilepsy'</a>.)</p><p class="headingAnchor" id="H890822111"><span class="h2">Cannabinoids</span><span class="headingEndMark"> — </span>Several randomized trials have demonstrated modest efficacy of a standardized preparation of cannabidiol oil in specific patient groups (eg, Dravet syndrome, Lennox-Gastaut syndrome) [<a href="#rid142">142-144</a>]. These data are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/101361.html" rel="external">"Seizures and epilepsy in children: Refractory seizures", section on 'Cannabinoids'</a> and  <a class="medical medical_review" href="/z/d/html/108722.html" rel="external">"Dravet syndrome: Management and prognosis", section on 'Cannabidiol'</a> and  <a class="medical medical_review" href="/z/d/html/138854.html" rel="external">"Lennox-Gastaut syndrome", section on 'Cannabidiol'</a>.)</p><p>Aside from Dravet syndrome and Lennox-Gastaut syndrome, high-quality data in humans are limited [<a href="#rid145">145-147</a>]. In 2018, a consortium of 25 epilepsy centers from the United States reported results from an expanded-access program supplying adjunctive cannabidiol to 607 children and adults with treatment-resistant epilepsies [<a href="#rid148">148</a>]. The median reduction in seizures at 12 and 96 weeks was approximately 50 percent. The withdrawal rate was 24 percent, mainly due to lack of efficacy and adverse events, the most common of which were diarrhea and somnolence.</p><p>Despite limited safety and efficacy data, marijuana use is common in patients with chronic epilepsy [<a href="#rid149">149</a>]. In a telephone survey of 136 adults with epilepsy followed at a tertiary care epilepsy clinic in Canada, 21 percent of patients reported active marijuana use; of these, two-thirds believed that marijuana improved their seizure severity [<a href="#rid150">150</a>]. In a multivariable analysis, significant predictors of marijuana use included seizure frequency (≥1 seizure per month), longer disease duration, and other illicit drug use.</p><p class="headingAnchor" id="H1499383521"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113971.html" rel="external">"Society guideline links: Seizures and epilepsy in adults"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span><span class="headingEndMark"> — </span>It is estimated that between 20 to 40 percent of patients with epilepsy will not have complete seizure control with antiseizure medication therapy alone.</p><p class="bulletIndent1"><span class="glyph">●</span>Prospective studies indicate that most patients with drug-resistant epilepsy (DRE) can be identified early in their presentation, after a failure of two antiseizure medication trials. (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Predictors of DRE include lack of efficacy of a first antiseizure medication trial, a high number of seizures prior to treatment, and a symptomatic/cryptogenic rather than idiopathic epilepsy syndrome. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with DRE have an increased risk of mortality as well as other disabilities including poor academic performance, unemployment, and other lifestyle restrictions. This provides an impetus for aggressive treatment. (See <a class="local">'Complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with DRE should undergo evaluation (usually video-EEG monitoring) to confirm the diagnosis of epilepsy; as many as 20 percent of patients with apparent DRE will have a nonepileptic paroxysmal disorder, usually psychogenic nonepileptic seizures  (<a class="graphic graphic_algorithm graphicRef139450" href="/z/d/graphic/139450.html" rel="external">algorithm 1</a>). EEG monitoring can also aid in seizure classification; findings should be correlated with the clinical history. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with localization-related DRE should have an MRI study to identify a potential surgical lesion. The sensitivity of MRI can be enhanced by the use of an epilepsy MRI protocol. Other neuroimaging studies (eg, single photon emission computed tomography [SPECT], positron emission tomography [PET]) can be employed in individuals in whom MRI does not show a lesion, in whom the MRI lesion does not correspond to the EEG localization, or who have dual pathology. (See <a class="local">'Neuroimaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We recommend surgical evaluation for patients with localization-related or partial epilepsy (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). MRI scan performed using an epilepsy protocol will often identify a lesion (eg, mesial temporal sclerosis, cortical dysplasia) amenable to surgical resection. The best efficacy for surgery is achieved in individuals with concordant localization of MRI and EEG abnormalities. For patients without an MRI lesion, an MRI lesion that is discordant with EEG findings, or with dual pathology, further neuroimaging studies can help identify an epileptic focus that might respond to surgical therapy. (See  <a class="medical medical_review" href="/z/d/html/91820.html" rel="external">"Surgical treatment of epilepsy in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients in whom epilepsy surgery is not an option or whose seizures persist after surgery, we suggest treatment trials with other antiseizure medications appropriate for their epilepsy syndrome and/or vagus nerve stimulation or responsive cortical stimulation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). While the chance of seizure remission with these treatments is not high, reductions in seizure frequency and improved quality of life are possible in most. (See  <a class="medical medical_review" href="/z/d/html/2229.html" rel="external">"Vagus nerve stimulation therapy for the treatment of epilepsy"</a> and <a class="local">'Antiseizure medications'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Begley CE, Famulari M, Annegers JF, et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 2000; 41:342.</a></li><li><a class="nounderline abstract_t">Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med 2011; 365:919.</a></li><li><a class="nounderline abstract_t">Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51:1069.</a></li><li><a class="nounderline abstract_t">Devinsky O. Patients with refractory seizures. N Engl J Med 1999; 340:1565.</a></li><li><a class="nounderline abstract_t">Berg AT, Kelly MM. Defining intractability: comparisons among published definitions. Epilepsia 2006; 47:431.</a></li><li><a class="nounderline abstract_t">Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342:314.</a></li><li><a class="nounderline abstract_t">Dlugos DJ, Sammel MD, Strom BL, Farrar JT. Response to first drug trial predicts outcome in childhood temporal lobe epilepsy. Neurology 2001; 57:2259.</a></li><li><a class="nounderline abstract_t">Berg AT, Shinnar S, Levy SR, et al. Early development of intractable epilepsy in children: a prospective study. Neurology 2001; 56:1445.</a></li><li><a class="nounderline abstract_t">Dlugos DJ. The early identification of candidates for epilepsy surgery. Arch Neurol 2001; 58:1543.</a></li><li><a class="nounderline abstract_t">Berg AT, Langfitt J, Shinnar S, et al. How long does it take for partial epilepsy to become intractable? Neurology 2003; 60:186.</a></li><li class="breakAll">Kwan P, Brodie M. Issues of medical intractability for surgical candidacy. In: The Treatment of Epilepsy and Practice, 4th ed, Wyllie E, Gupta A, Lachhwani D (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.983.</li><li><a class="nounderline abstract_t">Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology 2002; 58:S2.</a></li><li><a class="nounderline abstract_t">Brodie MJ, Barry SJ, Bamagous GA, et al. Patterns of treatment response in newly diagnosed epilepsy. Neurology 2012; 78:1548.</a></li><li><a class="nounderline abstract_t">Chen Z, Brodie MJ, Liew D, Kwan P. Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study. JAMA Neurol 2018; 75:279.</a></li><li><a class="nounderline abstract_t">Callaghan B, Schlesinger M, Rodemer W, et al. Remission and relapse in a drug-resistant epilepsy population followed prospectively. Epilepsia 2011; 52:619.</a></li><li><a class="nounderline abstract_t">Gilioli I, Vignoli A, Visani E, et al. Focal epilepsies in adult patients attending two epilepsy centers: classification of drug-resistance, assessment of risk factors, and usefulness of "new" antiepileptic drugs. Epilepsia 2012; 53:733.</a></li><li><a class="nounderline abstract_t">Choi H, Hayat MJ, Zhang R, et al. Drug-resistant epilepsy in adults: Outcome trajectories after failure of two medications. Epilepsia 2016; 57:1152.</a></li><li><a class="nounderline abstract_t">Bautista RE, Glen ET. Seizure severity is associated with quality of life independent of seizure frequency. Epilepsy Behav 2009; 16:325.</a></li><li><a class="nounderline abstract_t">Benbadis SR, Tatum WO, Vale FL. When drugs don't work: an algorithmic approach to medically intractable epilepsy. Neurology 2000; 55:1780.</a></li><li><a class="nounderline abstract_t">Kalilani L, Sun X, Pelgrims B, et al. The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis. Epilepsia 2018; 59:2179.</a></li><li><a class="nounderline abstract_t">Sultana B, Panzini MA, Veilleux Carpentier A, et al. Incidence and Prevalence of Drug-Resistant Epilepsy: A Systematic Review and Meta-analysis. Neurology 2021; 96:805.</a></li><li><a class="nounderline abstract_t">Bonnett L, Smith CT, Smith D, et al. Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial. Lancet Neurol 2012; 11:331.</a></li><li><a class="nounderline abstract_t">Hughes DM, Bonnett LJ, Czanner G, et al. Identification of patients who will not achieve seizure remission within 5 years on AEDs. Neurology 2018; 91:e2035.</a></li><li><a class="nounderline abstract_t">Sillanpää M. Remission of seizures and predictors of intractability in long-term follow-up. Epilepsia 1993; 34:930.</a></li><li><a class="nounderline abstract_t">Camfield PR, Camfield CS, Gordon K, Dooley JM. If a first antiepileptic drug fails to control a child's epilepsy, what are the chances of success with the next drug? J Pediatr 1997; 131:821.</a></li><li><a class="nounderline abstract_t">Perucca P, Hesdorffer DC, Gilliam FG. Response to first antiepileptic drug trial predicts health outcome in epilepsy. Epilepsia 2011; 52:2209.</a></li><li><a class="nounderline abstract_t">Callaghan BC, Anand K, Hesdorffer D, et al. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 2007; 62:382.</a></li><li><a class="nounderline abstract_t">Luciano AL, Shorvon SD. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 2007; 62:375.</a></li><li><a class="nounderline abstract_t">Schmidt D, Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 2005; 46:858.</a></li><li><a class="nounderline abstract_t">Kwan P, Brodie MJ. Drug treatment of epilepsy: when does it fail and how to optimize its use? CNS Spectr 2004; 9:110.</a></li><li><a class="nounderline abstract_t">Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology 2008; 70:54.</a></li><li><a class="nounderline abstract_t">Camfield C, Camfield P, Gordon K, et al. Outcome of childhood epilepsy: a population-based study with a simple predictive scoring system for those treated with medication. J Pediatr 1993; 122:861.</a></li><li><a class="nounderline abstract_t">Hitiris N, Mohanraj R, Norrie J, et al. Predictors of pharmacoresistant epilepsy. Epilepsy Res 2007; 75:192.</a></li><li><a class="nounderline abstract_t">MacDonald BK, Johnson AL, Goodridge DM, et al. Factors predicting prognosis of epilepsy after presentation with seizures. Ann Neurol 2000; 48:833.</a></li><li><a class="nounderline abstract_t">Del Felice A, Beghi E, Boero G, et al. Early versus late remission in a cohort of patients with newly diagnosed epilepsy. Epilepsia 2010; 51:37.</a></li><li><a class="nounderline abstract_t">Bilevicius E, Yasuda CL, Silva MS, et al. Antiepileptic drug response in temporal lobe epilepsy: a clinical and MRI morphometry study. Neurology 2010; 75:1695.</a></li><li><a class="nounderline abstract_t">French JA. Refractory epilepsy: clinical overview. Epilepsia 2007; 48 Suppl 1:3.</a></li><li><a class="nounderline abstract_t">Liimatainen SP, Raitanen JA, Ylinen AM, et al. The benefit of active drug trials is dependent on aetiology in refractory focal epilepsy. J Neurol Neurosurg Psychiatry 2008; 79:808.</a></li><li><a class="nounderline abstract_t">Geerts A, Brouwer O, Stroink H, et al. Onset of intractability and its course over time: the Dutch study of epilepsy in childhood. Epilepsia 2012; 53:741.</a></li><li><a class="nounderline abstract_t">Semah F, Picot MC, Adam C, et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998; 51:1256.</a></li><li><a class="nounderline abstract_t">Mohanraj R, Brodie MJ. Outcomes in newly diagnosed localization-related epilepsies. Seizure 2005; 14:318.</a></li><li><a class="nounderline abstract_t">Berg AT, Levy SR, Novotny EJ, Shinnar S. Predictors of intractable epilepsy in childhood: a case-control study. Epilepsia 1996; 37:24.</a></li><li><a class="nounderline abstract_t">Mohanraj R, Brodie MJ. Prediction of refractory epilepsy [abstract]. Epilepsia 2003; 44(Suppl 8):156.</a></li><li><a class="nounderline abstract_t">Stephen LJ, Kelly K, Mohanraj R, Brodie MJ. Pharmacological outcomes in older people with newly diagnosed epilepsy. Epilepsy Behav 2006; 8:434.</a></li><li><a class="nounderline abstract_t">Löscher W, Potschka H, Sisodiya SM, Vezzani A. Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options. Pharmacol Rev 2020; 72:606.</a></li><li><a class="nounderline abstract_t">Gesche J, Beier CP. Drug resistance in idiopathic generalized epilepsies: Evidence and concepts. Epilepsia 2022; 63:3007.</a></li><li><a class="nounderline abstract_t">Sillanpää M, Schmidt D. Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain 2006; 129:617.</a></li><li><a class="nounderline abstract_t">Camfield P, Camfield C. The frequency of intractable seizures after stopping AEDs in seizure-free children with epilepsy. Neurology 2005; 64:973.</a></li><li><a class="nounderline abstract_t">Schiller Y. Seizure relapse and development of drug resistance following long-term seizure remission. Arch Neurol 2009; 66:1233.</a></li><li><a class="nounderline abstract_t">Choi H, Heiman G, Pandis D, et al. Seizure remission and relapse in adults with intractable epilepsy: a cohort study. Epilepsia 2008; 49:1440.</a></li><li><a class="nounderline abstract_t">Berg AT, Levy SR, Testa FM, D'Souza R. Remission of epilepsy after two drug failures in children: a prospective study. Ann Neurol 2009; 65:510.</a></li><li><a class="nounderline abstract_t">Berg AT, Vickrey BG, Testa FM, et al. How long does it take for epilepsy to become intractable? A prospective investigation. Ann Neurol 2006; 60:73.</a></li><li><a class="nounderline abstract_t">Holmes GL, Engel J Jr. Predicting medical intractability of epilepsy in children: how certain can we be? Neurology 2001; 56:1430.</a></li><li><a class="nounderline abstract_t">Berg AT. The natural history of mesial temporal lobe epilepsy. Curr Opin Neurol 2008; 21:173.</a></li><li><a class="nounderline abstract_t">Pitkänen A, Sutula TP. Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy. Lancet Neurol 2002; 1:173.</a></li><li><a class="nounderline abstract_t">Bernhardt BC, Worsley KJ, Kim H, et al. Longitudinal and cross-sectional analysis of atrophy in pharmacoresistant temporal lobe epilepsy. Neurology 2009; 72:1747.</a></li><li><a class="nounderline abstract_t">Garbelli R, Frassoni C, Condorelli DF, et al. Expression of connexin 43 in the human epileptic and drug-resistant cerebral cortex. Neurology 2011; 76:895.</a></li><li><a class="nounderline abstract_t">Feldmann M, Asselin MC, Liu J, et al. P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. Lancet Neurol 2013; 12:777.</a></li><li><a class="nounderline abstract_t">Pedley TA, Hirano M. Is refractory epilepsy due to genetically determined resistance to antiepileptic drugs? N Engl J Med 2003; 348:1480.</a></li><li><a class="nounderline abstract_t">Teichgräber LA, Lehmann TN, Meencke HJ, et al. Impaired function of GABA(B) receptors in tissues from pharmacoresistant epilepsy patients. Epilepsia 2009; 50:1697.</a></li><li><a class="nounderline abstract_t">Toering ST, Boer K, de Groot M, et al. Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSC-cortical tubers. Epilepsia 2009; 50:1409.</a></li><li><a class="nounderline abstract_t">Tomson T. Mortality in epilepsy. J Neurol 2000; 247:15.</a></li><li><a class="nounderline abstract_t">Sperling MR, Feldman H, Kinman J, et al. Seizure control and mortality in epilepsy. Ann Neurol 1999; 46:45.</a></li><li><a class="nounderline abstract_t">Shackleton DP, Westendorp RG, Kasteleijn-Nolst Trenité DG, et al. Survival of patients with epilepsy: an estimate of the mortality risk. Epilepsia 2002; 43:445.</a></li><li><a class="nounderline abstract_t">Mohanraj R, Norrie J, Stephen LJ, et al. Mortality in adults with newly diagnosed and chronic epilepsy: a retrospective comparative study. Lancet Neurol 2006; 5:481.</a></li><li><a class="nounderline abstract_t">Friedman DE, Gilliam FG. Seizure-related injuries are underreported in pharmacoresistant localization-related epilepsy. Epilepsia 2010; 51:43.</a></li><li><a class="nounderline abstract_t">Luoni C, Bisulli F, Canevini MP, et al. Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia 2011; 52:2181.</a></li><li><a class="nounderline abstract_t">Ben-Menachem E, Schmitz B, Kälviäinen R, et al. The burden of chronic drug-refractory focal onset epilepsy: Can it be prevented? Epilepsy Behav 2023; 148:109435.</a></li><li><a class="nounderline abstract_t">Fisher RS, Vickrey BG, Gibson P, et al. The impact of epilepsy from the patient's perspective I. Descriptions and subjective perceptions. Epilepsy Res 2000; 41:39.</a></li><li><a class="nounderline abstract_t">Smith D, Defalla BA, Chadwick DW. The misdiagnosis of epilepsy and the management of refractory epilepsy in a specialist clinic. QJM 1999; 92:15.</a></li><li><a class="nounderline abstract_t">Bartolini E, Ferrari AR, Lattanzi S, et al. Drug-resistant epilepsy at the age extremes: Disentangling the underlying etiology. Epilepsy Behav 2022; 132:108739.</a></li><li><a class="nounderline abstract_t">Renganathan R, Delanty N. Juvenile myoclonic epilepsy: under-appreciated and under-diagnosed. Postgrad Med J 2003; 79:78.</a></li><li><a class="nounderline abstract_t">Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998; 39:5.</a></li><li><a class="nounderline abstract_t">Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav 2002; 3:338.</a></li><li><a class="nounderline abstract_t">Kyngäs H. Predictors of good compliance in adolescents with epilepsy. Seizure 2001; 10:549.</a></li><li><a class="nounderline abstract_t">Schuele SU, Lüders HO. Intractable epilepsy: management and therapeutic alternatives. Lancet Neurol 2008; 7:514.</a></li><li><a class="nounderline abstract_t">Szaflarski JP, Ficker DM, Cahill WT, Privitera MD. Four-year incidence of psychogenic nonepileptic seizures in adults in hamilton county, OH. Neurology 2000; 55:1561.</a></li><li><a class="nounderline abstract_t">Gates JR, Ramani V, Whalen S, Loewenson R. Ictal characteristics of pseudoseizures. Arch Neurol 1985; 42:1183.</a></li><li><a class="nounderline abstract_t">Neligan A, Holdright DR, Rugg-Gunn FJ, Sander JW. A case of mistaken mesial temporal identity. BMJ 2009; 338:b2258.</a></li><li><a class="nounderline abstract_t">Lüders HO, Turnbull J, Kaffashi F. Are the dichotomies generalized versus focal epilepsies and idiopathic versus symptomatic epilepsies still valid in modern epileptology? Epilepsia 2009; 50:1336.</a></li><li><a class="nounderline abstract_t">Quek AM, Britton JW, McKeon A, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol 2012; 69:582.</a></li><li><a class="nounderline abstract_t">Yoo JY, Panov F. Identification and Treatment of Drug-Resistant Epilepsy. Continuum (Minneap Minn) 2019; 25:362.</a></li><li><a class="nounderline abstract_t">Ryvlin P, Rheims S, Hirsch LJ, et al. Neuromodulation in epilepsy: state-of-the-art approved therapies. Lancet Neurol 2021; 20:1038.</a></li><li><a class="nounderline abstract_t">Neligan A, Bell GS, Elsayed M, et al. Treatment changes in a cohort of people with apparently drug-resistant epilepsy: an extended follow-up. J Neurol Neurosurg Psychiatry 2012; 83:810.</a></li><li><a class="nounderline abstract_t">Sancho J, Iváñez V, Molins A, et al. Changes in seizure severity and quality of life in patients with refractory partial epilepsy. Epilepsy Behav 2010; 19:409.</a></li><li><a class="nounderline abstract_t">Costa J, Fareleira F, Ascenção R, et al. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia 2011; 52:1280.</a></li><li><a class="nounderline abstract_t">Sperling MR, O'Connor MJ, Saykin AJ, Plummer C. Temporal lobectomy for refractory epilepsy. JAMA 1996; 276:470.</a></li><li><a class="nounderline abstract_t">Engel J Jr, Wiebe S, French J, et al. Practice parameter: temporal lobe and localized neocortical resections for epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons. Neurology 2003; 60:538.</a></li><li><a class="nounderline abstract_t">Jehi L, Jette N, Kwon CS, et al. Timing of referral to evaluate for epilepsy surgery: Expert Consensus Recommendations from the Surgical Therapies Commission of the International League Against Epilepsy. Epilepsia 2022; 63:2491.</a></li><li><a class="nounderline abstract_t">Cascino GD, Brinkmann BH. Advances in the Surgical Management of Epilepsy: Drug-Resistant Focal Epilepsy in the Adult Patient. Neurol Clin 2021; 39:181.</a></li><li><a class="nounderline abstract_t">Radhakrishnan K, So EL, Silbert PL, et al. Predictors of outcome of anterior temporal lobectomy for intractable epilepsy: a multivariate study. Neurology 1998; 51:465.</a></li><li><a class="nounderline abstract_t">Cukiert A, Cukiert CM, Argentoni M, et al. Outcome after corticoamygdalohippocampectomy in patients with refractory temporal lobe epilepsy and mesial temporal sclerosis without preoperative ictal recording. Epilepsia 2009; 50:1371.</a></li><li><a class="nounderline abstract_t">Kalamangalam GP, Tandon N. Stereo-EEG Implantation Strategy. J Clin Neurophysiol 2016; 33:483.</a></li><li><a class="nounderline abstract_t">Englot DJ. A modern epilepsy surgery treatment algorithm: Incorporating traditional and emerging technologies. Epilepsy Behav 2018; 80:68.</a></li><li><a class="nounderline abstract_t">Englot DJ, Ouyang D, Garcia PA, et al. Epilepsy surgery trends in the United States, 1990-2008. Neurology 2012; 78:1200.</a></li><li><a class="nounderline abstract_t">Jette N, Quan H, Tellez-Zenteno JF, et al. Development of an online tool to determine appropriateness for an epilepsy surgery evaluation. Neurology 2012; 79:1084.</a></li><li><a class="nounderline abstract_t">Simpson HD, Schulze-Bonhage A, Cascino GD, et al. Practical considerations in epilepsy neurostimulation. Epilepsia 2022; 63:2445.</a></li><li><a class="nounderline abstract_t">Skrehot HC, Englot DJ, Haneef Z. Neuro-stimulation in focal epilepsy: A systematic review and meta-analysis. Epilepsy Behav 2023; 142:109182.</a></li><li><a class="nounderline abstract_t">A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. The Vagus Nerve Stimulation Study Group. Neurology 1995; 45:224.</a></li><li><a class="nounderline abstract_t">DeGiorgio CM, Schachter SC, Handforth A, et al. Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures. Epilepsia 2000; 41:1195.</a></li><li><a class="nounderline abstract_t">Murphy JV. Left vagal nerve stimulation in children with medically refractory epilepsy. The Pediatric VNS Study Group. J Pediatr 1999; 134:563.</a></li><li><a class="nounderline abstract_t">Hosain S, Nikalov B, Harden C, et al. Vagus nerve stimulation treatment for Lennox-Gastaut syndrome. J Child Neurol 2000; 15:509.</a></li><li><a class="nounderline abstract_t">Touma L, Dansereau B, Chan AY, et al. Neurostimulation in people with drug-resistant epilepsy: Systematic review and meta-analysis from the ILAE Surgical Therapies Commission. Epilepsia 2022; 63:1314.</a></li><li><a class="nounderline abstract_t">Kuba R, Brázdil M, Novák Z, et al. Effect of vagal nerve stimulation on patients with bitemporal epilepsy. Eur J Neurol 2003; 10:91.</a></li><li><a class="nounderline abstract_t">Koutroumanidis M, Binnie CD, Hennessy MJ, et al. VNS in patients with previous unsuccessful resective epilepsy surgery: antiepileptic and psychotropic effects. Acta Neurol Scand 2003; 107:117.</a></li><li><a class="nounderline abstract_t">Amar AP, Apuzzo ML, Liu CY. Vagus nerve stimulation therapy after failed cranial surgery for intractable epilepsy: results from the vagus nerve stimulation therapy patient outcome registry. Neurosurgery 2004; 55:1086.</a></li><li><a class="nounderline abstract_t">Theodore WH, Fisher RS. Brain stimulation for epilepsy. Lancet Neurol 2004; 3:111.</a></li><li><a class="nounderline abstract_t">Cohen-Gadol AA, Britton JW, Wetjen NM, et al. Neurostimulation therapy for epilepsy: current modalities and future directions. Mayo Clin Proc 2003; 78:238.</a></li><li><a class="nounderline abstract_t">Peters TE, Bhavaraju NC, Frei MG, Osorio I. Network system for automated seizure detection and contingent delivery of therapy. J Clin Neurophysiol 2001; 18:545.</a></li><li><a class="nounderline abstract_t">Osorio I, Frei MG, Sunderam S, et al. Automated seizure abatement in humans using electrical stimulation. Ann Neurol 2005; 57:258.</a></li><li><a class="nounderline abstract_t">Morrell MJ, RNS System in Epilepsy Study Group. Responsive cortical stimulation for the treatment of medically intractable partial epilepsy. Neurology 2011; 77:1295.</a></li><li><a class="nounderline abstract_t">Heck CN, King-Stephens D, Massey AD, et al. Two-year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostimulation: final results of the RNS System Pivotal trial. Epilepsia 2014; 55:432.</a></li><li><a class="nounderline abstract_t">Bergey GK, Morrell MJ, Mizrahi EM, et al. Long-term treatment with responsive brain stimulation in adults with refractory partial seizures. Neurology 2015; 84:810.</a></li><li><a class="nounderline abstract_t">Devinsky O, Friedman D, Duckrow RB, et al. Sudden unexpected death in epilepsy in patients treated with brain-responsive neurostimulation. Epilepsia 2018; 59:555.</a></li><li><a class="nounderline abstract_t">Tellez-Zenteno JF, McLachlan RS, Parrent A, et al. Hippocampal electrical stimulation in mesial temporal lobe epilepsy. Neurology 2006; 66:1490.</a></li><li><a class="nounderline abstract_t">Velasco AL, Velasco F, Velasco M, et al. Electrical stimulation of the hippocampal epileptic foci for seizure control: a double-blind, long-term follow-up study. Epilepsia 2007; 48:1895.</a></li><li><a class="nounderline abstract_t">Velasco M, Velasco F, Velasco AL, et al. Subacute electrical stimulation of the hippocampus blocks intractable temporal lobe seizures and paroxysmal EEG activities. Epilepsia 2000; 41:158.</a></li><li><a class="nounderline abstract_t">Vonck K, Boon P, Achten E, et al. Long-term amygdalohippocampal stimulation for refractory temporal lobe epilepsy. Ann Neurol 2002; 52:556.</a></li><li><a class="nounderline abstract_t">Sprengers M, Vonck K, Carrette E, et al. Deep brain and cortical stimulation for epilepsy. Cochrane Database Syst Rev 2014; :CD008497.</a></li><li><a class="nounderline abstract_t">Lundstrom BN, Van Gompel J, Britton J, et al. Chronic Subthreshold Cortical Stimulation to Treat Focal Epilepsy. JAMA Neurol 2016; 73:1370.</a></li><li><a class="nounderline abstract_t">Lundstrom BN, Worrell GA, Stead M, Van Gompel JJ. Chronic subthreshold cortical stimulation: a therapeutic and potentially restorative therapy for focal epilepsy. Expert Rev Neurother 2017; 17:661.</a></li><li><a class="nounderline abstract_t">Kerezoudis P, Grewal SS, Stead M, et al. Chronic subthreshold cortical stimulation for adult drug-resistant focal epilepsy: safety, feasibility, and technique. J Neurosurg 2018; 129:533.</a></li><li><a class="nounderline abstract_t">Li MCH, Cook MJ. Deep brain stimulation for drug-resistant epilepsy. Epilepsia 2018; 59:273.</a></li><li><a class="nounderline abstract_t">Velasco F, Velasco M, Jiménez F, et al. Predictors in the treatment of difficult-to-control seizures by electrical stimulation of the centromedian thalamic nucleus. Neurosurgery 2000; 47:295.</a></li><li><a class="nounderline abstract_t">Sprengers M, Vonck K, Carrette E, et al. Deep brain and cortical stimulation for epilepsy. Cochrane Database Syst Rev 2017; 7:CD008497.</a></li><li><a class="nounderline abstract_t">Cukiert A, Cukiert CM, Burattini JA, et al. Seizure outcome after hippocampal deep brain stimulation in patients with refractory temporal lobe epilepsy: A prospective, controlled, randomized, double-blind study. Epilepsia 2017; 58:1728.</a></li><li><a class="nounderline abstract_t">Vetkas A, Fomenko A, Germann J, et al. Deep brain stimulation targets in epilepsy: Systematic review and meta-analysis of anterior and centromedian thalamic nuclei and hippocampus. Epilepsia 2022; 63:513.</a></li><li><a class="nounderline abstract_t">Fisher R, Salanova V, Witt T, et al. Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Epilepsia 2010; 51:899.</a></li><li><a class="nounderline abstract_t">Salanova V, Witt T, Worth R, et al. Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy. Neurology 2015; 84:1017.</a></li><li><a class="nounderline abstract_t">Salanova V, Sperling MR, Gross RE, et al. The SANTÉ study at 10 years of follow-up: Effectiveness, safety, and sudden unexpected death in epilepsy. Epilepsia 2021; 62:1306.</a></li><li><a class="nounderline abstract_t">Boon P, De Cock E, Mertens A, Trinka E. Neurostimulation for drug-resistant epilepsy: a systematic review of clinical evidence for efficacy, safety, contraindications and predictors for response. Curr Opin Neurol 2018; 31:198.</a></li><li><a class="nounderline abstract_t">Chen R, Classen J, Gerloff C, et al. Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation. Neurology 1997; 48:1398.</a></li><li><a class="nounderline abstract_t">Boroojerdi B, Prager A, Muellbacher W, Cohen LG. Reduction of human visual cortex excitability using 1-Hz transcranial magnetic stimulation. Neurology 2000; 54:1529.</a></li><li><a class="nounderline abstract_t">Menkes DL, Gruenthal M. Slow-frequency repetitive transcranial magnetic stimulation in a patient with focal cortical dysplasia. Epilepsia 2000; 41:240.</a></li><li><a class="nounderline abstract_t">Tergau F, Naumann U, Paulus W, Steinhoff BJ. Low-frequency repetitive transcranial magnetic stimulation improves intractable epilepsy. Lancet 1999; 353:2209.</a></li><li><a class="nounderline abstract_t">Theodore WH, Hunter K, Chen R, et al. Transcranial magnetic stimulation for the treatment of seizures: a controlled study. Neurology 2002; 59:560.</a></li><li><a class="nounderline abstract_t">Fregni F, Otachi PT, Do Valle A, et al. A randomized clinical trial of repetitive transcranial magnetic stimulation in patients with refractory epilepsy. Ann Neurol 2006; 60:447.</a></li><li><a class="nounderline abstract_t">Seynaeve L, Devroye A, Dupont P, Van Paesschen W. Randomized crossover sham-controlled clinical trial of targeted low-frequency transcranial magnetic stimulation comparing a figure-8 and a round coil to treat refractory neocortical epilepsy. Epilepsia 2016; 57:141.</a></li><li><a class="nounderline abstract_t">Chen R, Spencer DC, Weston J, Nolan SJ. Transcranial magnetic stimulation for the treatment of epilepsy. Cochrane Database Syst Rev 2016; :CD011025.</a></li><li><a class="nounderline abstract_t">DeGiorgio CM, Soss J, Cook IA, et al. Randomized controlled trial of trigeminal nerve stimulation for drug-resistant epilepsy. Neurology 2013; 80:786.</a></li><li><a class="nounderline abstract_t">Soss J, Heck C, Murray D, et al. A prospective long-term study of external trigeminal nerve stimulation for drug-resistant epilepsy. Epilepsy Behav 2015; 42:44.</a></li><li><a class="nounderline abstract_t">Devinsky O, Cross JH, Laux L, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med 2017; 376:2011.</a></li><li><a class="nounderline abstract_t">O'Connell BK, Gloss D, Devinsky O. Cannabinoids in treatment-resistant epilepsy: A review. Epilepsy Behav 2017; 70:341.</a></li><li><a class="nounderline abstract_t">Devinsky O, Patel AD, Cross JH, et al. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med 2018; 378:1888.</a></li><li><a class="nounderline abstract_t">Friedman D, Devinsky O. Cannabinoids in the Treatment of Epilepsy. N Engl J Med 2015; 373:1048.</a></li><li><a class="nounderline abstract_t">Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev 2014; :CD009270.</a></li><li><a class="nounderline abstract_t">Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014; 82:1556.</a></li><li><a class="nounderline abstract_t">Szaflarski JP, Bebin EM, Comi AM, et al. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results. Epilepsia 2018; 59:1540.</a></li><li><a class="nounderline abstract_t">Sulak D, Saneto R, Goldstein B. The current status of artisanal cannabis for the treatment of epilepsy in the United States. Epilepsy Behav 2017; 70:328.</a></li><li><a class="nounderline abstract_t">Gross DW, Hamm J, Ashworth NL, Quigley D. Marijuana use and epilepsy: prevalence in patients of a tertiary care epilepsy center. Neurology 2004; 62:2095.</a></li></ol></div><div id="topicVersionRevision">Topic 2214 Version 62.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10714408" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The cost of epilepsy in the United States: an estimate from population-based clinical and survey data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21899452" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Drug-resistant epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19889013" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10332020" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Patients with refractory seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16499772" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Defining intractability: comparisons among published definitions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10660394" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Early identification of refractory epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11756607" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Response to first drug trial predicts outcome in childhood temporal lobe epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11402099" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Early development of intractable epilepsy in children: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11594910" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The early identification of candidates for epilepsy surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12552028" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : How long does it take for partial epilepsy to become intractable?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12552028" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : How long does it take for partial epilepsy to become intractable?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11971127" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Staged approach to epilepsy management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22573629" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Patterns of treatment response in newly diagnosed epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29279892" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21269287" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Remission and relapse in a drug-resistant epilepsy population followed prospectively.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22360822" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Focal epilepsies in adult patients attending two epilepsy centers: classification of drug-resistance, assessment of risk factors, and usefulness of "new" antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27265407" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Drug-resistant epilepsy in adults: Outcome trajectories after failure of two medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19713158" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Seizure severity is associated with quality of life independent of seizure frequency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11188984" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : When drugs don't work: an algorithmic approach to medically intractable epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30426482" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33722992" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Incidence and Prevalence of Drug-Resistant Epilepsy: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22377180" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30389894" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Identification of patients who will not achieve seizure remission within 5 years on AEDs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8404749" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Remission of seizures and predictors of intractability in long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9427884" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : If a first antiepileptic drug fails to control a child's epilepsy, what are the chances of success with the next drug?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21973181" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Response to first antiepileptic drug trial predicts health outcome in epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17880009" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Likelihood of seizure remission in an adult population with refractory epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17253624" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Results of treatment changes in patients with apparently drug-resistant chronic epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15946327" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999167" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Drug treatment of epilepsy: when does it fail and how to optimize its use?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18166707" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Quantifying the response to antiepileptic drugs: effect of past treatment history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8501560" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Outcome of childhood epilepsy: a population-based study with a simple predictive scoring system for those treated with medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17628429" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Predictors of pharmacoresistant epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11117539" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Factors predicting prognosis of epilepsy after presentation with seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19490039" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Early versus late remission in a cohort of patients with newly diagnosed epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21060092" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Antiepileptic drug response in temporal lobe epilepsy: a clinical and MRI morphometry study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17316406" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Refractory epilepsy: clinical overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17991701" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The benefit of active drug trials is dependent on aetiology in refractory focal epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22417003" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Onset of intractability and its course over time: the Dutch study of epilepsy in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9818842" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Is the underlying cause of epilepsy a major prognostic factor for recurrence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15876543" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Outcomes in newly diagnosed localization-related epilepsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8603620" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Predictors of intractable epilepsy in childhood: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prediction of refractory epilepsy [abstract]</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16388987" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pharmacological outcomes in older people with newly diagnosed epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32540959" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36102351" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Drug resistance in idiopathic generalized epilepsies: Evidence and concepts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16401617" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15781810" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The frequency of intractable seizures after stopping AEDs in seizure-free children with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19822778" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Seizure relapse and development of drug resistance following long-term seizure remission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18410367" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Seizure remission and relapse in adults with intractable epilepsy: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19475671" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Remission of epilepsy after two drug failures in children: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16685695" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : How long does it take for epilepsy to become intractable? A prospective investigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11402096" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Predicting medical intractability of epilepsy in children: how certain can we be?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18317276" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The natural history of mesial temporal lobe epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12849486" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19246420" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Longitudinal and cross-sectional analysis of atrophy in pharmacoresistant temporal lobe epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21383325" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Expression of connexin 43 in the human epileptic and drug-resistant cerebral cortex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23786896" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12686705" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Is refractory epilepsy due to genetically determined resistance to antiepileptic drugs?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19453710" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Impaired function of GABA(B) receptors in tissues from pharmacoresistant epilepsy patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19220410" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSC-cortical tubers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10701892" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Mortality in epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10401779" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Seizure control and mortality in epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11952777" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Survival of patients with epilepsy: an estimate of the mortality risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16713919" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Mortality in adults with newly diagnosed and chronic epilepsy: a retrospective comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19519796" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Seizure-related injuries are underreported in pharmacoresistant localization-related epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22136077" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37748414" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The burden of chronic drug-refractory focal onset epilepsy: Can it be prevented?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10924867" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The impact of epilepsy from the patient's perspective I. Descriptions and subjective perceptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10209668" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The misdiagnosis of epilepsy and the management of refractory epilepsy in a specialist clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35636351" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Drug-resistant epilepsy at the age extremes: Disentangling the underlying etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12612320" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Juvenile myoclonic epilepsy: under-appreciated and under-diagnosed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9578007" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Antiepileptic drugs as a cause of worsening seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12609331" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The relationship between poor medication compliance and seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11792154" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Predictors of good compliance in adolescents with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18485315" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Intractable epilepsy: management and therapeutic alternatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11094115" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Four-year incidence of psychogenic nonepileptic seizures in adults in hamilton county, OH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3933461" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Ictal characteristics of pseudoseizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19549648" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : A case of mistaken mesial temporal identity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19389146" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Are the dichotomies generalized versus focal epilepsies and idiopathic versus symptomatic epilepsies still valid in modern epileptology?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22451162" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Autoimmune epilepsy: clinical characteristics and response to immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30921014" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Identification and Treatment of Drug-Resistant Epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34710360" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Neuromodulation in epilepsy: state-of-the-art approved therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22733083" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Treatment changes in a cohort of people with apparently drug-resistant epilepsy: an extended follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20855235" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Changes in seizure severity and quality of life in patients with refractory partial epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21729036" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8691555" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Temporal lobectomy for refractory epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12601090" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Practice parameter: temporal lobe and localized neocortical resections for epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35842919" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Timing of referral to evaluate for epilepsy surgery: Expert Consensus Recommendations from the Surgical Therapies Commission of the International League Against Epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33223082" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Advances in the Surgical Management of Epilepsy: Drug-Resistant Focal Epilepsy in the Adult Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9710020" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Predictors of outcome of anterior temporal lobectomy for intractable epilepsy: a multivariate study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18717712" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Outcome after corticoamygdalohippocampectomy in patients with refractory temporal lobe epilepsy and mesial temporal sclerosis without preoperative ictal recording.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27918343" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Stereo-EEG Implantation Strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29414561" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : A modern epilepsy surgery treatment algorithm: Incorporating traditional and emerging technologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22442428" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Epilepsy surgery trends in the United States, 1990-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22895589" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Development of an online tool to determine appropriateness for an epilepsy surgery evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35700144" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Practical considerations in epilepsy neurostimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36972642" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Neuro-stimulation in focal epilepsy: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7854516" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. The Vagus Nerve Stimulation Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10999559" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10228290" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Left vagal nerve stimulation in children with medically refractory epilepsy. The Pediatric VNS Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10961788" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Vagus nerve stimulation treatment for Lennox-Gastaut syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35352349" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Neurostimulation in people with drug-resistant epilepsy: Systematic review and meta-analysis from the ILAE Surgical Therapies Commission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12535002" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Effect of vagal nerve stimulation on patients with bitemporal epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12580861" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : VNS in patients with previous unsuccessful resective epilepsy surgery: antiepileptic and psychotropic effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15509315" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Vagus nerve stimulation therapy after failed cranial surgery for intractable epilepsy: results from the vagus nerve stimulation therapy patient outcome registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14747003" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Brain stimulation for epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12583536" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Neurostimulation therapy for epilepsy: current modalities and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11779967" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Network system for automated seizure detection and contingent delivery of therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668970" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Automated seizure abatement in humans using electrical stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21917777" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Responsive cortical stimulation for the treatment of medically intractable partial epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24621228" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Two-year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostimulation: final results of the RNS System Pivotal trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25616485" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Long-term treatment with responsive brain stimulation in adults with refractory partial seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29336029" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Sudden unexpected death in epilepsy in patients treated with brain-responsive neurostimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16554495" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Hippocampal electrical stimulation in mesial temporal lobe epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17634064" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Electrical stimulation of the hippocampal epileptic foci for seizure control: a double-blind, long-term follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10691112" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Subacute electrical stimulation of the hippocampus blocks intractable temporal lobe seizures and paroxysmal EEG activities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12402252" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Long-term amygdalohippocampal stimulation for refractory temporal lobe epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24937707" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Deep brain and cortical stimulation for epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27654625" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Chronic Subthreshold Cortical Stimulation to Treat Focal Epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28532252" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Chronic subthreshold cortical stimulation: a therapeutic and potentially restorative therapy for focal epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29053073" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Chronic subthreshold cortical stimulation for adult drug-resistant focal epilepsy: safety, feasibility, and technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29218702" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Deep brain stimulation for drug-resistant epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10942002" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Predictors in the treatment of difficult-to-control seizures by electrical stimulation of the centromedian thalamic nucleus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28718878" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Deep brain and cortical stimulation for epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28744855" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Seizure outcome after hippocampal deep brain stimulation in patients with refractory temporal lobe epilepsy: A prospective, controlled, randomized, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34981509" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Deep brain stimulation targets in epilepsy: Systematic review and meta-analysis of anterior and centromedian thalamic nuclei and hippocampus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20331461" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25663221" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33830503" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : The SANTÉstudy at 10 years of follow-up: Effectiveness, safety, and sudden unexpected death in epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29493559" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Neurostimulation for drug-resistant epilepsy: a systematic review of clinical evidence for efficacy, safety, contraindications and predictors for response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9153480" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10751273" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Reduction of human visual cortex excitability using 1-Hz transcranial magnetic stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10691123" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Slow-frequency repetitive transcranial magnetic stimulation in a patient with focal cortical dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10392988" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Low-frequency repetitive transcranial magnetic stimulation improves intractable epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12196649" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Transcranial magnetic stimulation for the treatment of seizures: a controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17068786" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : A randomized clinical trial of repetitive transcranial magnetic stimulation in patients with refractory epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26642974" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Randomized crossover sham-controlled clinical trial of targeted low-frequency transcranial magnetic stimulation comparing a figure-8 and a round coil to treat refractory neocortical epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27513825" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Transcranial magnetic stimulation for the treatment of epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23365066" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Randomized controlled trial of trigeminal nerve stimulation for drug-resistant epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25499162" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : A prospective long-term study of external trigeminal nerve stimulation for drug-resistant epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28538134" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28188044" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Cannabinoids in treatment-resistant epilepsy: A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29768152" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26352816" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Cannabinoids in the Treatment of Epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24595491" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Cannabinoids for epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24778283" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29998598" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28254350" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : The current status of artisanal cannabis for the treatment of epilepsy in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15184622" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Marijuana use and epilepsy: prevalence in patients of a tertiary care epilepsy center.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
